<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02991365</url>
  </required_header>
  <id_info>
    <org_study_id>8 weeks study</org_study_id>
    <nct_id>NCT02991365</nct_id>
  </id_info>
  <brief_title>Effect of Weight Loss on Brain Insulin Sensitivity in Humans</brief_title>
  <official_title>Effekt Von Gewichtsabnahme Auf Die zentralnervöse Insulinresistenz Des Menschen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity if known to be associated with brain insulin resistance in humans. This condition has
      not only implication for the brain but also for whole-body energy homeostasis. Research in
      rodents indicates that weight loss is able to improve insulin sensitivity of the brain. The
      current project will test this hypothesis in humans. Therefore, brain insulin sensitivity
      will be assessed by fMRI in combination with intranasal insulin administration, using an
      established protocol. Furthermore, effects of daily administration of insulin nasal spray
      (versus placebo) over 8 weeks will be assessed as secondary (exploratory) variables.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>brain insulin sensitivity</measure>
    <time_frame>30 minutes after administration of nasal insulin</time_frame>
    <description>fMRI measurement will be performed before and after administration of 160 U of human insulin as nasal spray. Changes in regional activity will be quantified to assess regional brain insulin sensitivity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of daily administration of 160 U nasal insulin or placebo over 8 weeks on body weight.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Participants will receive nasal insulin or placebo in a double-blind randomized fashion. Before and after 8 weeks body weight will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of daily administration of 160 U nasal insulin or placebo over 8 weeks on glucose tolerance .</measure>
    <time_frame>8 weeks</time_frame>
    <description>Participants will receive nasal insulin or placebo in a double-blind randomized fashion. Before and after 8 weeks glucose tolerance will be assessed using a 75 g oral glucose tolerance test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of daily administration of 160 U nasal insulin or placebo over 8 weeks on body composition .</measure>
    <time_frame>8 weeks</time_frame>
    <description>Participants will receive nasal insulin or placebo in a double-blind randomized fashion. Before and after 8 weeks body composition will be addressed by whole-body MRI and liver MRS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>whole-body insulin sensitivity</measure>
    <time_frame>2 hours</time_frame>
    <description>Insulin sensitivity will be estimated from a frequent-sampling 75 g oral glucose tolerance test using the Matsuda formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>2 hours</time_frame>
    <description>a 75 g oral glucose tolerance test will be performed. Glucose tolerance will be defined by the American Diabetes Association criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>1 hours</time_frame>
    <description>cognitive function will be addressed by neuropsychological testing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>nasal insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>daily administration of 160 U of human insulin as nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>daily administration of placebo solution as nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nasal insulin</intervention_name>
    <arm_group_label>nasal insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo spray</intervention_name>
    <arm_group_label>placebo spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HbA1c &lt;6.5%

          -  Age between 40 and 75 years

          -  No intake of antidiabetic drugs or drugs for weight reduction

          -  no steroid intake

          -  Stable medication over 10 weeks before the start of the study

        Exclusion Criteria:

          -  Persons who wear non-removable metal parts in or on the body.

          -  Persons with reduced temperature sensitivity and / or increased sensitivity to heating
             of the body

          -  Cardiovascular disease can not be ruled out, e.g. manifest coronary heart disease,
             heart failure greater than NYHA 2, previous heart attack, stroke condition

          -  Persons with hearing impairment or increased sensitivity to loud noises

          -  People with claustrophobia

          -  Minors or non-consenting subjects are also excluded

          -  Subjects with an operation less than 3 months

          -  Simultaneous participation in other studies

          -  Neurological and psychiatric disorders

          -  Subjects with hemoglobin Hb &lt;11 g / dl

          -  Hypersensitivity to any of the substances used
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andreas Fritsche, MD</last_name>
    <phone>+49 7071 29 80687</phone>
    <email>andreas.fritsche@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Tuebingen, Department of Internal Medicine IV</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Fritsche, Prof. Dr.</last_name>
      <phone>+49 7071 29 82714</phone>
      <email>andreas.fritsche@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Heni, Dr.</last_name>
      <phone>+49 7071 29 82714</phone>
      <email>martin.heni@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Heni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

